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Abstract: 
Objective: Mast cells are tissue-resident immune sentinels that are implicated in the 
pathogenesis of inflammatory joint disease. The aim of this study was to test our hypothesis that 
complement fragments could be key activators of synovial mast cells in autoimmune arthritis. 
Methods: In vivo studies used the murine K/BxN arthritis model, a distal symmetric 
polyarthritis mediated by IgG immune complexes. Expression of C5aR on synovial mast cells 
was determined by immunohistochemical and functional studies. C5aR−/− and control mast cells 
were engrafted into mast cell–deficient WBB6 F1-Kitw/KitW-v (W/Wv) mice to examine the 
requirement for this receptor in arthritis. C5aR-dependent activation of mast cells was 
investigated in C5aR−/− animals and in murine and human mast cell cultures. 
Results: Murine synovial mast cells express functional C5aR. Unlike their wild-type 
counterparts, C5aR−/− mast cells adoptively transferred into W/Wv mice were not competent to 
restore arthritis, despite equivalent synovial engraftment. Activation of C5aR−/− mast cells by 
K/BxN serum in vivo remained intact, indicating that C5aR is dispensable for normal IgG-
mediated triggering. Consistent with this result, cultured mast cells treated with C5a failed to 
modulate the expression of Fcγ receptors (FcγR) or to otherwise alter the activation threshold. In 
human mast cells, C5a promoted the production of the neutrophil chemotaxin interleukin-8, and 
recruitment of neutrophils at 24 hours after serum administration was impaired in C5aR−/− mice, 
suggesting that enhanced neutrophil chemoattractant production underlies the requirement for 
C5aR on mast cells in arthritis. 
Conclusion: Stimulation via C5aR is required to unleash the proinflammatory activity of 
synovial mast cells in immune complex arthritis, albeit via a mechanism that is distinct from 
C5a-modulated expression of FcγR. 
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Article: 
The pathogenesis of the idiopathic inflammatory arthritides involves both adaptive and innate 
immune cells, as well as mesenchymal cell lineages such as the synovial fibroblast. In some of 
these conditions, including rheumatoid arthritis (RA), strong evidence has accumulated that 
antibodies play a key role in the translation of impaired immune tolerance to inflammation in the 
joint. Autoantibodies such as rheumatoid factor and anti–citrullinated peptide antibodies are 
common in RA, while the joints of seropositive RA patients are encrusted with immune 
complexes and display marked activation of complement via both classical and alternative 
pathways (for review, see ref.1). 
The effector phase of immune complex–driven arthritis has been modeled in multiple murine 
systems, including collagen-induced arthritis and K/BxN arthritis. These models share many key 
features, including a dependence on both IgG Fcγ receptors (FcγR) and complement, as well as 
effector pathways, such as the proinflammatory cytokine interleukin-1 (IL-1) (2). Multiple innate 
immune lineages have been implicated in the inflammatory reaction to articular immune 
complexes in these models, including neutrophils and macrophages (3, 4). We and other 
investigators have demonstrated a role of the synovial mast cell in this process, at least in certain 
genetic backgrounds (5–7). These hematopoietically derived cells make up ∼3% of the cells in the 
normal synovial sublining, where they take up residence in perivascular and perineural tissues 
and immediately deep to the synovial lining (8, 9). Given their relatively limited numbers, mast 
cells are thought to act as sentinels, rapidly liberating a broad range of mediators that mobilize 
adaptive and innate immune responders, including circulating neutrophils. In this way, mast cells 
have been shown to facilitate resistance to bacterial peritonitis (10, 11), and we have hypothesized 
that they play a similar role in surveillance of the vulnerable synovial space (9). 
In immune complex arthritis, this sentinel function becomes maladaptive. In addition to receptors 
for IgE, mast cells express Fcγ receptors and can be readily activated by IgG immune complexes. 
K/BxN serum–transfer arthritis is mediated by IgG antibodies that form immune complexes with 
their autoantigen glucose-6-phosphate isomerase, and several strains of mast cell–deficient mice 
are resistant to disease induction (5, 6). Resistance can be overcome by engraftment with cultured 
mast cells, confirming that mast cells can play a key role in arthritis susceptibility (5). Recently, 
we elucidated the mechanisms that underlie this activity, finding that synovial mast cells become 
activated by immune complex binding to FcγRIII, resulting in the release of IL-1 and potentially 
of other mediators that “jump start” inflammation within the joint (12). 
However, mast cells can express receptors besides FcγR that are of potential relevance in 
arthritis. These include receptors for the complement anaphylatoxins C3a and C5a, which are 
generated through the activation of complement by immune complexes and are readily 
demonstrable in RA synovial fluid (1, 13, 14). We hypothesized that complement receptors could 
synergize with FcγR to promote the proinflammatory activity of the synovial mast cell. 
Precedent for such an interaction is strong. Rat macrophages activated via both FcγR and C5a 
have been shown to produce an expanded repertoire of mediators of inflammation (15). More 
recently, elegant studies of murine macrophages have shown that C5a can reciprocally modulate 
the expression of activating (FcγRIII) and inhibitory (FcγRII) Fcγ receptors, leading to a cellular 
state of enhanced susceptibility to immune complex activation (16–19). This mechanism has been 
detailed down to the molecular level, where a 2-bp difference in the promoters for these 
receptors has been found to account for their differential response to C5aR-initiated intracellular 
signaling (20, 21). 
Modulation of FcγR expression represents an important mechanism by which the activation of 
leukocytes that are transiently exposed to immune complexes could be limited (22). However, it 
remains unclear whether this mechanism is active in all cells that express C5aR and FcγR. In 
particular, mast cells acquire a functional phenotype only upon maturation within the tissues and 
would be expected to have little “incidental” contact with immune complexes. We therefore 
studied whether complement receptors participate in mast cell effector activity in inflammatory 
arthritis and whether such participation depends on complement-mediated modulation of the 
threshold to activation via Fcγ receptors. 
MATERIALS AND METHODS 
Mice. 
C5aR−/− and C3aR−/− mice were derived as described previously (23, 24). WBB6 F1-Kitw/KitW-
v (W/Wv), WBB6 littermate controls, C57BL/6J (B6), B6;129S4-Fcgr2btm1Ttk/J (FcγRII−/−), 
B6.129P2-Fcgr3tm1Sjv/J (FcγRIII−/−), and B6;129P2-Fcer1gtm1Rav/J (FcRγ−/−) animals were 
purchased from The Jackson Laboratory. C57BL/6-KitW-sh/W-sh (Wsh) mice (25) were maintained 
at The Jackson Laboratory. Animals were housed in the specific pathogen–free animal facilities 
of the Dana-Farber Cancer Institute or Children's Hospital Boston. All procedures were approved 
by the appropriate animal care and use committees. 
Antibodies and reagents. 
Antibodies used for cytofluorometric analysis of human cells included phycoerythrin (PE)–
conjugated CD16, CD32A/B (clone AT10), and CD64 (Caltag); fluorescein isothiocyanate 
(FITC)–conjugated C5aR and Alexa Fluor 488–conjugated C3aR (AbD Serotec); and Alexa 
Fluor 488–conjugated anti-FcγRIIb (2B6; gift of MacroGenics) (26); and matched isotype 
controls. Reagents for murine cytofluorometry included anti-C5aR (20/70; gift of J. Zwirner 
[27]), PE-conjugated anti-FcγRII/III (2.4G2) and PE–Cy7–conjugated anti-CD45 (BD 
PharMingen), carboxyfluorescein-conjugated anti-FcγRIII (clone 275003; R&D Systems), FITC-
conjugated anti-CD11b (Caltag), and Alexa Fluor 647–conjugated Gr-1 (Caltag), as well as 
matched isotype controls. Unlabeled anti-FcγRIII was used as a blocking reagent prior to 
staining with PE-conjugated 2.4G2 to assess surface expression of FcγRII, as described 
elsewhere (21). Anti–human FcγRIIa antibodies were purified from clone IV.3 supernatants 
(American Type Culture Collection). Rabbit anti-murine C5a receptor antiserum for 
immunohistochemistry was generated as described previously (28). Recombinant human stem cell 
factor (SCF) was purchased from Research Diagnostics or PeproTech. Recombinant human C5a, 
recombinant mouse SCF, and enzyme-linked immunosorbent assay (ELISA) reagents were 
purchased from R&D Systems. Recombinant mouse IL-3 was purchased from Pierce. Flow 
cytometry was performed using a FACSDiva cytometer (Becton Dickinson). 
Cell culture and stimulation. 
Murine bone marrow–derived mast cells (BMMCs) were used following at least 4 weeks of 
culture in 12.5 ng/ml of recombinant mouse SCF and 10 ng/ml of recombinant mouse IL-3, as 
described elsewhere (5). To accomplish FcγRIII-mediated stimulation in vitro, lipopolysaccharide 
(LPS)–free 2.4G2 was coated overnight at 4°C onto a high-binding ELISA plate (Costar 9018) at 
100 μl/well in 0.2Ncarbonate buffer, pH 8. Plates were washed twice with Dulbecco's modified 
Eagle's medium (DMEM). Mast cells were resuspended in 200 μl of fresh cytokine-free BMMC 
medium per well and then centrifuged at 900 revolutions per minute (160g) for 1 minute to 
initiate contact between cells and bound antibody. 
Human skin mast cells (SMCs) were cultured from tissue obtained at abdominoplasty in X-Vivo 
media (BioWhittaker) and 100 ng/ml of recombinant human SCF, as described previously (29). 
To generate the FcγRIIa crosslinking reagent, anti–human FcγRIIa antibody IV.3 was incubated 
for 45 minutes at 37°C with goat F(ab′)2 fragments directed against murine Fab (Sigma); the 
concentration of reagents was optimized for each IV.3 batch and varied from 1 μg/ml to 20 
μg/ml for IV.3 and from 0.6 μg/ml to 5 μg/ml for anti-mouse F(ab′)2. Warm crosslinking reagent 
was added at the volume indicated for a final well volume of 200 μl. The release of β-
hexosaminidase was quantified by colorimetric assay and was expressed as a percentage of total 
cellular β-hexosaminidase, as determined by ultrasonic lysis of parallel wells. For both human 
and murine mast cells, the cells were washed into media containing fresh cytokines 1 day prior to 
experimentation. At initiation of each experiment, the cells were resuspended in warm cytokine-
free medium. 
Analysis of calcium flux. 
Cells were washed into calcium-containing buffer (Hanks' balanced salt solution plus 1 gm/liter 
of bovine serum albumin, 1 mM CaCl2, and 1 mM MgCl2) and incubated for 30 minutes at 37°C 
with Fura 2 AM (2.5 μl/ml; Molecular Probes). Following a further wash, cells were resuspended 
at 0.5–1 × 106/ml in the same buffer, and calcium-sensitive fluorescence was read using a 
Hitachi F-4500 fluorescence spectrophotometer. 
Quantitative polymerase chain reaction (PCR). 
Total RNA and complementary DNA were generated using standard commercial kits (Qiagen). 
PCR for murine Fcγ receptors II and III was performed using published primers (30). Alternate 
validated primers were used in some experiments, with similar results; these were as follows: for 
FcγRII, 5′-AGAAGCTGCCAAAACTGAGG-3′ (forward) and 5′-
CTTCGGGATGCTTGAGAAGTG-3′ (reverse); for FcγRIII 5′-
CAGAATGCACACTCTGGAAGC-3′ (forward) and 5′-GGGTCCCTTCGCACATCA-3′ 
(reverse); and for GAPDH 5′-AGGTCGGTGTGAACGGATTTG-3′ (forward) and 5′-
TGTAGACCATGTAGTTGAGGTCA-3′ (reverse). GAPDH primers were confirmed to have 
stable expression under all experimental conditions. Data were analyzed using the 2  method. 
Induction of arthritis and measurement of paw swelling. 
Arthritis was induced by intraperitoneal administration of 150 μl of serum obtained from arthritic 
K/BxN mice and was scored as described previously (5). Briefly, each paw was scored from 0 (no 
inflammation) to 3 (maximal inflammation), and the results were summed to arrive at an overall 
clinical index. Acute paw swelling was determined immediately prior to serum injection. Spring-
loaded calipers were used to measure the thickness of each paw: for the forepaw, measurement 
across the dorsal–ventral axis with the paw in neutral position; for the ankle, measurement across 
the malleoli with the ankle in full flexion. Measurements were repeated 30 minutes following 
serum injection to quantitate changes in thickness over this interval (“flare”). 
A similar technique was used to quantitate acute edema following periarticular instillation of 
C5a. In these experiments, 20 μl of a concentrated stock solution of C5a (400 nM in LPS-free 
phosphate buffered saline [PBS]) were injected into the dorsal wrist or lateral ankle tissue of 
otherwise unmanipulated animals. A similar volume of PBS alone was instilled into the 
contralateral wrist and ankle. The solutions were distributed through the tissues by brief 
massage, and the joints were then measured at baseline and after 10 minutes to assess acute 
edema. 
Engraftment of cultured mast cells. 
BMMCs were engrafted into mast cell–deficient W/Wv mice by injection into the tail vein 
(107 cells per recipient), as described previously (5). Experiments were initiated 10 weeks after 
cell transfer. Engraftment was quantified by microscopic examination of three 20× high-power 
fields in each ankle, as determined by an examiner (PAN) who was blinded to treatment group 
(12). 
Microscopy. 
For immunohistochemical staining, histology sections were deparaffinized and subjected to 
antigen retrieval in sodium citrate buffer, pH 6.0, for 15 minutes at 86°C. After blocking with 
normal goat serum, samples were incubated overnight at 4°C with 10 μg/ml of primary antibody, 
for 30 minutes with biotinylated secondary antibody (Vector), for 30 minutes with avidin–
biotin–alkaline phosphatase ABC reagent (Vector), and finally, for 20 minutes with 1 mg/ml of 
fast red substrate (Sigma). Tissues were counterstained with Gill's hematoxylin no. 2. To assess 
degranulation, ankles were stained with toluidine blue and examined in a blinded manner to 
identify mast cells demonstrating granule exocytosis, as described elsewhere (5). Neutrophil 
infiltration was assessed by staining with the antineutrophil antibody NIMP-R14 after antigen 
retrieval with proteinase K, as described previously (31), followed by microscopic analysis to 
enumerate the number of infiltrating NIMP-R14+ cells in the 3 richest 40× fields. 
Neutrophil recruitment assay. 
For functional assessment of a C5aR-dependent, BMMC-derived neutrophil chemoattractant, 
250,000 FcγRII−/− BMMCs in 1 ml of 2% fetal bovine serum (FBS)/BMMC media per well, in 
the presence or absence of 50 nM C5a, were spun onto a 12-well plate (Costar 3402) that had 
been coated overnight with carbonate buffer with or without 10 μg/ml of 2.4G2, as described 
above. After 20 minutes, polycarbonate Transwells with 3-μm pores were inserted into the wells, 
and whole bone marrow from a C5aR−/− mouse that had been resuspended in 0.1% FBS/DMEM 
was divided into the upper chambers. After 4 hours, the Transwells were removed, and the 
migrated neutrophils (defined as CD45+CD11bhighGr-1high) were enumerated by flow cytometry 
using added counting beads as a standard (catalog no. 18328; Polysciences). 
Statistical analysis. 
Results were compared using the Student's t-test. P values ≤ 0.05 were considered significant. 
Error bars reflect SEM. 
RESULTS 
In K/BxN arthritis, C5aR−/− animals are densely resistant to arthritis, a resistance that depends in 
part on a requirement for C5aR in neutrophils but could include other lineages (32, 33). However, 
the role of C3aR has not been examined. We therefore initiated arthritis by transfer of K/BxN 
mouse serum into C3aR−/− mice and found them to be normally susceptible to disease, as has 
previously been shown in studies of collagen antibody–induced arthritis (34) (Figure 1A). We 
therefore focused further study on the role of C5aR in synovial mast cells. 
 
Figure 1. A, C3aR−/− mice and matched wild-type (WT) controls were injected with K/BxN mouse serum 
on days 0 and 2. Clinical outcomes in the 2 groups were indistinguishable. Results are representative of 2 
independent experiments. Values are the mean ± SEM of 4 mice per group. B, Photomicrographs of ankle 
joint sections show mast cells lying just deep to the synovial lining in the tibiotalar joint, as indicated by 
toluidine blue staining (left), and bright staining for C5aR in an adjacent section (right). Staining with 
isotype control is shown in the inset. Results are representative of 4 experiments. (Original magnification 
× 400.) C, Instillation of C5a into the periarticular tissues of the wrist and ankle joints resulted in acute 
edema, as indicated by the change in paw thickness, in the C57BL/6 mice, but not the mast cell–deficient 
Wsh mice, after treatment with phosphate buffered saline (PBS) or C5a. Each data point represents a 
single mouse; horizontal lines show the mean. Mice were pooled from 2 experiments. NS = not 
significant. 
While expression of C5aR by mast cells has been well documented, the characteristics of an 
individual mast cell population depend strongly on the developmental stage and the tissue 
microenvironment (35, 36). Specifically, some murine mast cell populations do not express C5aR 
until they are activated by another signal (37). It was therefore important to demonstrate that C5aR 
was expressed and functional on synovial mast cells. Using immunohistochemical techniques, 
we demonstrated strong expression of C5aR on mast cells in the synovial sublining (Figure 1B). 
The function of this receptor was confirmed by instillation of C5a into periarticular tissues, 
resulting in measurable edema within 10 minutes in a mast cell–dependent manner (Figure 1C). 
We concluded that C5aR is expressed and functional on normal synovial mast cells and is 
therefore a potential participant in the activation of mast cells by immune complexes. 
To examine the role of C5aR on mast cells in isolation from other cell types, we used a genetic 
approach. BMMCs were cultured from wild-type and C5aR−/− animals and engrafted into mast 
cell–deficient animals using a standard technique (5, 12, 38). After 10 weeks, animals were injected 
with K/BxN serum, and arthritis susceptibility was monitored by clinical examination. Unlike 
wild-type mast cells, C5aR−/−BMMCs failed to restore arthritis susceptibility to W/Wv mice 
(Figure 2A). To ensure that this phenomenon did not reflect a failure of engraftment, ankle tissue 
from recipient animals was examined for mast cell density, which was found to be equivalent 
(Figure 2B). These data indicate that C5aR is dispensable for the migration of mast cells into 
synovial tissue but is required for the arthritogenic activity of these cells. 
 
Figure 2. A, W/Wv mice were engrafted for 10 weeks with bone marrow–derived mast cells (BMMCs) 
from B6 or C5aR−/− mice, followed by initiation of K/BxN arthritis. Results are representative of 5 
independent experiments. Values are the mean ± SEM of 5 mice per group. B, Engrafted mast cells in the 
ankle joints of the mice in A were quantified, and the results are shown. Each data point represents a 
single mouse (n = 23–26 per group); horizontal lines show the mean. NS = not significant; hpf = high-
power field. C, Paw edema (flare) before (top) and 30 minutes after (bottom) intraperitoneal injection of 
150 μl of K/BxN serum into a B6 mouse. D, Time course of paw edema (flare) in B6 mice following 
intraperitoneal (IP) injection of K/BxN serum. Results are representative of 4 experiments. Values are the 
mean ± SEM of 5 mice per group. E, Assessment of flare at 30 minutes after injection of K/BxN serum in 
B6, C5aR−/−, and mast cell–deficient (W/Wv) mice and in FcRγ−/− mice lacking Fcγ receptor III. Five of 
the B6 mice and 4 of the C5aR−/−mice received a second serum injection on day 2; their mean ± SEM 
clinical scores on day 7 were 11.6 ± 0.4 and 0 ± 0, respectively (P < 0.0001). Each data point represents a 
single mouse; horizontal lines show the mean. Mice were pooled from 3 experiments. F, Degranulation of 
synovial mast cells was assessed histologically 24 hours after administration of K/BxN serum in B6, 
C5aR−/−, and FcγRIII−/− mice. Values are the mean and SEM. 
The impact of C5aR on macrophage FcγR expression is well established. We therefore 
anticipated that C5aR on synovial mast cells would play a key permissive role in immune 
complex–mediated activation that is otherwise constrained by the presence of the inhibitory 
receptor FcγRII (39). We examined this hypothesis in 2 ways. First, we used a functional 
approach. Mice injected intravenously with K/BxN serum develop an acute, but transient, 
increase in paw microvascular permeability, which can be visualized with the technically 
demanding technique of intravital microscopy in anesthetized mice given high molecular weight 
intravascular dye (40). This vascular leak is dependent on mast cells (40). We observed that this 
phenomenon could be quantified in animals receiving serum via the usual intraperitoneal route 
by measuring paw thickness before and 30 minutes after the intraperitoneal injection (Figures 2C 
and D). We therefore injected K/BxN serum into C5aR−/− and control B6 animals, as well as 
negative control mast cell–deficient W/Wv and FcR γ−/−mice lacking FcγRIII. Despite profound 
arthritis resistance in C5aR−/− animals, we found that vascular leak remained intact in these 
animals (Figure 2E). This finding is consistent with the published observation that C5aR−/− mice 
exhibit typical dye extravasation after intravenous administration of serum in the more involved 
assay (40). 
Our second approach to the assessment of mast cell activation was by direct histologic 
examination for granule exocytosis. We examined sections of ankles harvested from wild-type, 
C5aR−/−, and negative control FcγRIII−/− animals 24 hours after administration of K/BxN serum, 
a time point at which degranulation is readily apparent (5). Consistent with the vascular leak 
result, degranulation of C5aR−/− mast cells was indistinguishable from that of mast cells from B6 
controls and greater than that of mast cells lacking the relevant activating FcγR (Figure 2F). 
These studies confirm that IgG-dependent activation of synovial mast cells in K/BxN serum–
transfer arthritis does not require costimulation via C5a and suggest that C5aR-mediated changes 
in FcγR expression may be less important in mast cells than in macrophages. 
To corroborate this observation, we investigated C5aR-mediated FcγR expression and activation 
in cultured mast cells. Murine BMMCs express both the inhibitory receptor FcγRII and the 
activating receptor FcγRIII (39). Expression of C5aR on these cells was confirmed by flow 
cytometry (Figure 3A). Function was confirmed by a calcium flux assay, in which C5a uniformly 
induced a brisk signal in B6 BMMCs, as assessed within 1 day of media change, that was absent 
in C5aR−/− BMMCs (Figure 3B). Contrary to our expectations, stimulation with C5a did not alter 
FcγRII or FcγRIII expression, as assessed by quantitative PCR as well as by specific surface 
staining (16, 17) (Figures3C and D). 
 
Figure 3. A, Bone marrow–derived mast cells (BMMCs) were stained with 20/70 antibody (rat anti-
mouse C5aR) (shaded histogram) or isotype control (open histogram), followed by a fluorescein 
isothiocyanate (FITC)–conjugated anti-rat antibody. FITC-A = fluorescence intensity. B, BMMCs from 
B6, but not C5aR−/−, mice exhibited calcium flux. Vehicle (V) and C5a (100 nM) were added at the 
indicated time points (seconds). Calcium flux was absent in BMMCs from “spent” media (data not 
shown), so refreshed cells were used for all experiments. Values are arbitrary units. C, B6 mouse 
BMMCs exposed to 100 nM C5a or vehicle were harvested at 2 hours for measurement of Fcγ receptor 
(FcγR) mRNA by quantitative polymerase chain reaction analysis. Shown are the results from 2 separate 
BMMC cultures, each of which was stimulated in triplicate. Data are expressed as the ratio of FcγRIII to 
FcγRII and are representative of 3 experiments at 2 hours as well as 3 experiments at 4 hours (data not 
shown). Values are the mean and SEM. D, B6 mouse BMMCs stimulated with 50 nM C5a or vehicle 
were harvested at the indicated times and tested for FcγR expression by flow cytometry. No effect of 
stimulation was observed. Values are the mean and SEM of pooled data from 2 experiments, each of 
which included 2 separate BMMC cultures. MFI = mean fluorescence intensity. 
Consistent with this result, C5a did not promote FcγRIII-mediated activation of B6 or 
FcγRII−/− BMMCs, as assessed by the β-hexosaminidase assay for degranulation or by 
production of the cytokine IL-6 (Figure 4). Note that C5a alone was not a potent activator of 
BMMCs, inducing degranulation of 0–5% of cells and no appreciable production of IL-6 in 
unstimulated cells (Figure 4, vehicle data). Multiple experiments failed to identify conditions in 
which C5a could modulate BMMC activation as assessed by these parameters, including dose 
ranging (1–500 nM C5a), time course (stimulation with C5a for up to 24 hours before or 4 hours 
after FcγR ligation), and conditioning experiments as well as costimulation with other potentially 
relevant ligands, including C3a (0–100 nM), LPS (0–10 μg/ml), IL-1β (10 ng/ml), IL-4 (10 
ng/ml), transforming growth factor β (10 ng/ml), IL-33 (10 ng/ml), and IL-3–deficient and/or 
high levels of SCF (250 ng/ml) culture conditions (data not shown). Similarly, stimulation of the 
phenotypically more mature peritoneal-derived mast cells (41) with C5a together with IgG 
immune complexes failed to demonstrate a change in activation parameters, although the 
expression of functional C5aR could not be established conclusively in this model cell (data not 
shown). 
 
Figure 4. Bone marrow–derived mast cells (BMMCs) from B6 or FcγRII−/−mice were spun onto a plate 
coated with the anti-FcγRII/III antibody 2.4G2, in the presence of vehicle or 100 nM C5a, and after 
overnight incubation, supernatants from duplicate wells were harvested. The percentage release of β-
hexosaminidase (top) and the amount of interleukin-6 (IL-6) (bottom) in the supernatants were 
determined. Note the logarithmic scale for the IL-6 data. Degranulation remained suppressed in BMMCs 
from B6 mice, although low levels of IL-6 production could be detected in some experiments, as shown 
here. Results are representative of at least 3 separate experiments. 
While these results mirrored our in vivo findings, we wished to replicate our experiments in a 
model cell relevant to human disease. We therefore tested the effect of C5a on human connective 
tissue mast cells cultured from skin explants. SMCs display a mature mast cell protease 
phenotype and can be activated via surface FcγRIIa, although they do not express the inhibitory 
receptor FcγRIIb (29, 42). Mast cells resident in human skin express C5aR (43), and we confirmed 
by cytofluorometric and C5a-mediated calcium flux analyses that this phenotype was maintained 
in cultured SMCs (Figures 5A and B). Furthermore, C5a was competent to activate SMCs, if 
only modestly (Figure 5C). However, as with BMMCs, C5a failed to modulate surface 
expression of FcγR in SMCs (Figure 5D). Stimulation with C5a did not shift the dose-response 
curve of activation via FcγRIIa, although degranulation effects were additive (Figure 6A). 
 
Figure 5. A, Human skin mast cells (SMCs) were stained with anti-C5aR antibody (shaded histogram) or 
with isotype control (open histogram) and assessed by flow cytometry. C3aR was not detectable (data not 
shown). FITC-A = fluorescein isothiocyanate (fluorescence intensity). B, Calcium flux was determined in 
human SMCs. Vehicle (V), C5a (100 nM), and adenosine triphosphate (ATP; positive control) were 
added at the indicated time points. Values are arbitrary units. Data shown in A and B are representative of 
2 experiments using distinct SMC cultures. C, Degranulation was determined in human SMCs treated for 
4–6 hours with 10 nM C5a. Degranulation was observed with as little as 1 nM C5a and did not increase 
measurably from 10–300 nM (data not shown). Values are the mean and SEM of 14 replicates per group 
pooled from 7 experiments. D, Human SMCs were stained for Fcγ receptor (FcγR) expression 2 hours 
after incubation with C5a 100 nM(shaded histogram) or vehicle (histogram with thick line) as compared 
with isotype control (histogram with thin line). Staining for FcγRI (CD64) remained absent, as did 2B6 
staining for FcγRIIB (data not shown). Data were confirmed in 3 SMC cultures performed in 2 separate 
experiments. 
 
Figure 6. A, Human skin mast cells (SMCs) were stimulated for 4 hours with graded concentrations of 
Fcγ receptor IIa (FcγRIIa) crosslinker, with or without 10 nM C5a. The FcγRIIa crosslinking reagent was 
generated from anti–human FcγRIIa antibody IV.3 as described in Materials and Methods. C5a 
contributed to SMC degranulation but did not alter the responsiveness to FcγRIIa. B, Human SMCs were 
stimulated for 4 hours with 10 nM C5a, 5 μl of FcγRIIa crosslinker, or both, and interleukin-8 (IL-8) 
levels were determined. Results in A and B are representative of 5 independent experiments using SMCs 
from 2 donors. C, Bone marrow–derived mast cells (BMMCs) from FcγRII−/− mice were placed in the 
bottom of a Transwell system and were left unstimulated (no stim) or were stimulated with 50 nM C5a, 
10 μg/ml of 2.4G2, or both. The migration of C5aR−/− mouse neutrophils from the upper chamber was 
determined at 4 hours by flow cytometry. Stimulation with C5a did not result in enhanced migration. 
Experiments were also performed in the absence of BMMCs. Results are representative of 2 
experiments. D, The presence of extravasated NIMP-R14+ neutrophils was assessed 24 hours after 
intraperitoneal instillation of 200 μl of K/BxN serum into normal, C5aR−/−, or B6 mice (n = 5 mice [9 
ankles] per group). Values in B–D are the mean and SEM. ∗∗ = P < 0.01. NS = not significant. 
If C5aR is not required for IgG-mediated activation of mast cells, what is the contribution of this 
receptor to the function of mast cells in arthritis? The most likely possibility is that C5a enables 
the production of a mediator that is vital to the evolution of synovitis, either alone or in 
conjunction with FcγR ligation. We have previously shown that mast cells are a key source of 
IL-1 in early synovitis, and this mediator is elaborated by BMMCs upon activation via FcγR (12). 
However, despite extensive study in this model cell, we were unable to demonstrate an effect of 
C5a, with or without concomitant FcγR ligation, on the synthesis of IL-1α or IL-1β protein, the 
processing of IL-1β from its 31-kd precursor to the active 17-kd cytokine, or the release of active 
cytokine into the environment (data not shown). 
In analogous experiments, we were unable to demonstrate an effect of C5a on BMMC 
production of arachidonate metabolites (leukotriene B4, prostaglandin D2) or a large set of 
candidate cytokines and chemokines, which were assessed via dedicated ELISAs, PCR, or 
multiplex techniques (Pierce SearchLight, R&D Systems Proteome Profiler Mouse Cytokine 
Antibody Array) (data not shown). However, in human SMCs stimulated via FcγRIIa, C5a could 
reproducibly enhance the production of the neutrophil chemoattractant IL-8 (Figure 6B). This 
effect was specific, in that TNF production remained unaffected; IL-1β could not be detected 
(data not shown). These results suggest that the interaction between C5a and FcγR in synovial 
mast cells is likely to be one of synergy in the production of key proinflammatory factors, 
potentially including one or more neutrophil chemoattractants. 
We therefore returned to the murine system to evaluate neutrophil chemoattractants as potential 
C5a-driven mast cell mediators. IL-8 is not expressed in mice, but is instead represented by a 
family of related neutrophil chemoattractants that are ligands for the murine counterpart of the 
human IL-8 receptors CXCR1 and CXCR2, including macrophage inflammatory protein 2 (MIP-
2), granulocyte chemotactic protein 2 (GCP-2), neutrophil-activating peptide 2 (NAP-2), 
keratinocyte chemoattractant (KC), and lipopolysaccharide-induced CXC chemokine (LIX). 
Individual investigation of each of these mediators in BMMCs stimulated via C5a, with or 
without FcγR ligation, revealed no consistent changes in protein production (MIP-2 and KC, as 
well as the CCR5 ligand MIP-1α, which was also tested), or for those without a commercially 
available ELISA, no consistent changes in gene expression (GCP-2, NAP-2, and LIX) (data not 
shown). 
To ensure that we had not missed a chemoattractant using this candidate approach, we addressed 
the question functionally. BMMCs stimulated via C5a, FcγR ligation, or both were placed in the 
bottom of a Transwell chamber with C5aR−/− neutrophils (as whole bone marrow) in the upper 
chamber. Whereas FcγR-stimulated BMMCs elaborated potent chemoattractants, no effect of 
C5a alone was observed, and no increment was noted with the combination stimulus (Figure 6C). 
We concluded that we were unable to demonstrate a C5a-dependent neutrophil chemoattractant 
from our model cell. 
Thus, we sought supportive evidence of a role for C5aR in neutrophil infiltration in vivo, via 
immunohistologic staining of ankle tissues with the neutrophil marker NIMP-R14 (31). Tissues 
harvested from B6 and C5aR−/− mice 30 minutes after serum administration, which was at the 
peak of the “flare,” demonstrated no infiltration of neutrophils or other recognizable lineages into 
ankle tissues of either B6 or C5aR−/−mice (data not shown). However, at 24 hours, scattered foci 
of infiltrating neutrophils could be demonstrated in most WT mice (7 of 9 ankles examined), 
while these remained absent in C5aR−/− animals (Figure 6D). We cannot exclude the possibility 
that this effect simply represents impaired migration of C5aR-deficient neutrophils. However, we 
have recently shown that C5aR−/− neutrophils can migrate to inflamed joints if drawn by a non-
C5a stimulus (33). Thus, these data support the possibility that C5aR is involved broadly in the 
generation of neutrophil chemoattractants in arthritis. Together with the data from our 
engraftment studies, they are consistent with the hypothesis that C5aR on mast cells promotes 
the formation of one or more neutrophil chemoattractants. The identity of such chemoattractants 
or other C5aR-dependent mast cell mediators remains undefined. 
DISCUSSION 
Innate immune cells are key players in autoimmune synovitis. Among these are mast cells, which 
populate the normal joint in small numbers but can expand 10-fold as arthritis progresses (44). 
The contribution of these cells to joint inflammation is likely complex. At initiation of disease, 
mast cells can serve as first sensors of immune complexes, contributing both to rapid increases in 
local vasopermeability and to the recruitment of inflammatory cells, an activity we have called 
the “jump start” (12, 40). In established disease, where an expanded population of mast cells is 
often present, their contribution is as yet largely unexplored. Levels of mast cell–derived 
mediators, such as heparin and proteases, are elevated in synovial fluid from the joints of both 
RA and osteoarthritis (OA) patients, and proteases of the tryptase family have been implicated 
experimentally in cartilage injury (9, 31). Other potential functions of mast cells in the diseased 
joint include recruitment of inflammatory cells, promotion of antigen-directed adaptive immune 
responses, growth of new blood vessels, development of fibrosis, and degradation of 
proinflammatory mediators to help terminate inflammation (for review, see ref.9). Indeed, since 
mast cells from rheumatoid joints are phenotypically diverse (45, 46), different populations of 
mast cells could exert distinct effects. 
The current study focuses on the role of the C5a receptor in murine synovial mast cells at the 
initiation of arthritis. We found that C5aR expression is required to allow mast cells to 
accomplish their proinflammatory activity. We found no evidence that C5aR modulates the 
susceptibility of mast cells to immune complex–mediated activation in the joint or in model cells 
studied in vitro, and we therefore conclude that mast cells can diverge in this respect from 
murine macrophages. Since the phenotype of mast cells is strongly conditioned by the 
microenvironment, our results do not exclude the possibility that mast cells exhibit such 
modulation under other conditions. In the context of the arthritic “jump start” studied here, 
however, C5aR plays a different role. Most probably, C5aR synergizes with FcγRIII to promote 
the synthesis of critical mediators, as has been reported in rat alveolar macrophages (15). We 
could not demonstrate this phenomenon in BMMCs, perhaps reflecting the developmental 
immaturity of these cells (35). However, synergy between C5a and FcγR on the production of IL-
8 by human SMCs confirmed that such a mechanism can occur in mast cells, and histologic data 
were consistent with the hypothesis that C5aR on mast cells participates in neutrophil 
recruitment to the joint. 
The relevance of mast cell C5aR to human disease remains to be determined. Mast cells isolated 
from RA synovium, but not those from OA synovium, have been shown to express C5aR and to 
be capable of mediator release upon activation via C5a (46). Expression of C5aR on mast cells in 
healthy synovium is unknown. Blockade of C5a/C5aR in established RA has thus far yielded 
disappointing results, although effective antagonism at the level of synovial tissue was not 
confirmed (47, 48). Since C5a is present at physiologically relevant levels in human RA synovial 
fluid, it would be surprising if this mediator had no effect on C5aR-bearing synovial mast cells 
(14). 
Interestingly, while immune complexes fix complement and are likely a major source of synovial 
C5a, this anaphylatoxin can be generated in other ways. Hepatic macrophages can elaborate C5, 
and synthesis of C5 within rheumatoid synovial tissue has been detected in some studies, 
although its cellular source is unclear (1, 19). Cleavage into C5a can be accomplished by proteases 
other than C3 convertase, including mast cell tryptase (49). This finding may explain why mice 
lacking C3 (and therefore incapable of complement-mediated C5 proteolysis) are less densely 
resistant to K/BxN arthritis than mice lacking C5aR (32). Similar results have been observed in 
the cutaneous immune complex–mediated Arthus reaction, immune complex alveolitis, and 
autoimmune hemolytic anemia (18, 19, 50). The implication of these results is that C5aR on mast 
cells could contribute to joint inflammation even in diseases not mediated by immune 
complexes. 
Together with previous results (12), the current findings demonstrate that the participation of mast 
cells in immune complex–driven murine inflammatory arthritis is dependent codominantly upon 
FcγR and C5aR. The need for activation via both pathways does not reside in alterations of FcγR 
expression or the activation threshold but reflects the contribution of C5a to the elaboration of 
arthritogenic mediators, including neutrophil chemoattractants. These results define a novel 
pathway of interaction between complement and FcγR ligation in mast cells that may play an 
important part in the pathogenesis of immune complex–mediated disease, including 
inflammatory arthritis. 
Addendum. 
Since the time this article was accepted for publication, another group of investigators has 
reported the identification of IL-17A in human synovial mast cells and has shown that this 
mediator may be elaborated by cultured human mast cells in a C5a-dependent manner (51). While 
IL-17A was included in our multiplex assays, it was not detected in our study samples, though 
we cannot exclude that the sensitivity of the assay was inadequate to detect a relevant signal. 
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